A phase II study of acalabrutinib in combination with R-CHOP for previously untreated transplant-ineligible mantle cell lymphoma patients in Spain (the SOUND-MCL Study)
Por:
Niebla, AM, Garcia-Sancho, AM, Garcia, JC, Garcia, EA, Mellen, AC and Sancho, JM
Publicada:
1 dic 2025
Ahead of Print:
1 dic 2025
Resumen:
Filiaciones:
Niebla, AM:
Hosp Univ Vall Hebron, Vall Hebron Inst Oncol VHIO, Hematol Dept, Barcelona, Spain
Garcia-Sancho, AM:
Univ Salamanca, Hosp Univ Salamanca, IBSAL, CIBERONC,Hematol Dept, Salamanca, Spain
Garcia, JC:
AstraZeneca Farmaceut Spain, Med Dept, Madrid, Spain
Garcia, EA:
AstraZeneca Farmaceut Spain, Med Dept, Madrid, Spain
Mellen, AC:
AstraZeneca Farmaceut Spain, Med Dept, Madrid, Spain
:
ICO IJC Badalona Hosp Germans Trias i Pujol, Hematol Dept, Badalona, Spain
|